Recent Advances in Glycyrrhetinic Acid-Functionalized Biomaterials for Liver Cancer-Targeting Therapy.

Abstract

Liver cancer is one of the most common causes of cancer mortality worldwide. Chemotherapy and radiotherapy are the conventional therapies generally employed in patients with liver tumors. The major issue associated with the administration of chemotherapeutics is their high toxicity and lack of selectivity, leading to systemic toxicity that can be detrimental to the patient's quality of life. An important approach to the development of original liver-targeted therapeutic products takes advantage of the employment of biologically active ligands able to bind specific receptors on the cytoplasmatic membranes of liver cells. In this perspective, glycyrrhetinic acid (GA), a pentacyclic triterpenoid present in roots and rhizomes of licorice, has been used as a ligand for targeting the liver due to the expression of GA receptors on the sinusoidal surface of mammalian hepatocytes, so it may be employed to modify drug delivery systems (DDSs) and obtain better liver or hepatocyte drug uptake and efficacy. In the current review, we focus on the most recent and interesting research advances in the development of GA-based hybrid compounds and DDSs developed for potential employment as efficacious therapeutic options for the treatment of hepatic cancer.

• Authors: Antonio Speciale, Claudia Muscarà, Maria Sofia Molonia, Mariateresa Cristani, Francesco Cimino, Antonella Saija
• Journal: Molecules (Basel, Switzerland) (Molecules) Vol. 27 Issue 6 (Mar 08 2022) ISSN: 1420-3049 [Electronic] Switzerland
• PMID: 35335138 (Publication Type: Journal Article, Review)

Chemical References

• Biocompatible Materials
• Glycyrrhetinic Acid

Topics

• Animals
• Biocompatible Materials (therapeutic use)
• Glycyrrhetinic Acid
• Humans
• Liver Neoplasms (drug therapy, metabolism)
• Mammals
• Quality of Life